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Background: Upper respiratory tract infections (URTIs), including rhinitis, nasopharyngi-
tis, tonsillitis and otitis media (OM), comprise of 88% of total respiratory infections, espe-
cially in children. Therefore effective prevention and treatment of RTIs remain a high 
priority worldwide. Preclinical and clinical data highlight the rationale for the use and ef-
fectiveness of immunity‐targeted approaches, including targeted immunisations and non‐
specific immunomodulation in the prevention and management of recurrent upper RTIs.
Objective of review: The idea of this review was to summarise the current evidence and 
address key questions concerning the use of conservative and immunity‐targeted ap-
proaches to recurrent and chronic URTIs, with a focus on the paediatric population.
Search strategy/Evaluation method: Literature searches were conducted in March 
2017 and updated in September 2017 using: Academic Search Complete; CENTRAL; 
Health Source: Nursing/Academic Edition; MEDLINE; clinicaltrials.gov; and Cochrane 
databases. In total, 84 articles were retrieved and reviewed. Two independent re-
searchers focused on primary and secondary endpoints in systematic reviews, meta‐
analyses and randomised, controlled trials, using immunity‐directed strategies as the 
control group or within a subpopulation of larger studies. Existing guidelines and in-
terventional/observational studies on novel applications were also included.
Results: Children are particularly susceptible to RTIs due to the relative immaturity of 
their immune systems, as well as other potential predisposing factors such as day care 
attendance and/or toxic environmental factors (eg increased pathogenic microbial ex-
posure and air pollutants). Recurrent URTIs can affect otherwise healthy children, 
leading to clinical sequelae and complications, including the development of chronic 
conditions or the need for surgery. Available pre‐clinical and clinical data highlight the 
rationale for the use and effectiveness of immunity‐targeted approaches, including 
targeted immunisations (flu and pneumococcal vaccines) and non‐specific immu-
nomodulation (bacterial lysates), in the prevention and management of recurrent 
croup, tonsillitis, otitis media, recurrent acute rhinosinusitis and chronic rhinosinusitis.
Conclusions: In this review, we summarise the current evidence and provide data 
demonstrating that some immunity‐targeted strategies, including vaccination and 
immunomodulation, have proved effective in the treatment and prevention of recur-
rent and chronic URTIs in children.
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1  | RESPIR ATORY TR AC T INFEC TIONS
1.1 | Introduction
Upper respiratory tract infections (URTIs; also known as ENT infec-
tions), including rhinitis, nasopharyngitis, tonsillitis and otitis media 
(OM), comprise 88% of total respiratory infections.1 The aetiology 
of URTIs is mostly viral, being primarily caused by rhinovirus (HRV), 
parainfluenza, respiratory syncytial virus (RSV), influenza, adeno-
virus and coronavirus. Upper respiratory tract infections are more 
common in the autumn/winter in Europe and North America, and 
during the rainy season in tropical countries.2
Children are prone to developing RTIs because their immune sys-
tem has yet to fully mature.3-5 Increased exposure to viral infections 
during day care attendance, as well as other social and environmen-
tal factors, can increase the risk of RTI.4 The respiratory system is a 
primary target for key air pollutants, which can increase the risk of 
acute and recurrent RTIs.6 Most of these pollutants disrupt local mu-
cosal innate immunity mechanisms, leading to bacterial colonisation, 
impaired killing and increased allergen permeability.
1.2 | Burden and management of RTIs
URTIs are associated with sequelae and complications, including se-
vere lower RTIs (LRTIs), the development of chronic conditions or 
the need for surgery when recurrent. Owing to the high morbidity, 
mortality and healthcare costs, effective prevention and treatment 
of RTIs are a high priority worldwide.7,8 Treatment is focused on 
symptom relief, such as antihistamines and decongestants for nasal 
congestion9 and antitussives for cough.10,11 Although antibiotics are 
only indicated in a minority of patients, they are often unnecessarily 
prescribed for viral infections against which they have no effect. A 
recent US report highlighted that ~30% of outpatient, oral antibi-
otic prescriptions were inappropriately written.12 Antibiotic misuse 
has led to the emergence of resistant bacteria, meaning that higher 
doses and more advanced generations of drugs are required, and at 
present, some infected patients cannot be treated adequately.13
Owing to the current unmet need for effective, alternative 
conservative therapies, efforts are being refocused towards pre-
ventative strategies including5 behavioural intervention; avoidance 
of environmental risk factors such as passive smoking14 and highly 
polluted city areas; vaccination, such as active targeted immunisa-
tion; targeted medical intervention; non‐specific immunostimulation 
or immunomodulation (eg bacterial lysates)15‐18; nutrition, including 
vitamins (eg C or D) and microelements; and regular physical activity 
(Table 1). Parents of children with recurrent RTIs may also discuss 
“immune‐stimulating” therapies that they have seen advertised, such 
as herbal (eg Echinacea) and homoeopathic remedies, and animal‐
derived products (eg cod liver oil and thymus extracts).5 Owing to 
significant heterogeneity and a lack of high‐quality clinical evidence 
supporting many of these therapies,19 here we reviewed existing im-
munity‐targeted therapies available for ENT infections in children, 
with an emphasis on non‐specific immunomodulation administered 
together with the standard of care.
1.3 | Role of immunomodulation in respiratory 
tract infections
Immunomodulatory strategies treat RTIs by enhancing local and sys-
temic immune responses. Systemic effects relate to the use of mi-
crobial‐derived preparations (bacterial lysates, bacterial ribosomes) 
that display effects such as increased systemic polyclonal immuno-
globulin (Ig) synthesis (both IgA and IgG classes) and activation of 
several populations of immunocompetent cells (including CD4+ lym-
phocytes, natural killer cells, and B lymphocytes).20 These effects 
have consequently been reported in both in vitro and in vivo experi-
ments (for review, see Kearney et al).21
A number of clinical studies have shown that bacterial lysates 
and bacterial organelles (eg ribosomes), when applied orally, are 
effective in preventing both URTI and LRTIs in children, decreas-
ing the number, duration and severity of infectious episodes, 
Key points
• Upper RTIs comprise 88% of total respiratory infections
• Children are particularly susceptible to RTIs because 
their immune system has yet to fully mature
• Recurrent URTIs can affect otherwise healthy children, 
leading to clinical sequelae and complications
• Owing to the high morbidity, mortality and healthcare 
costs, effective prevention and treatment of RTIs are a 
high priority worldwide
• Pre‐clinical and clinical data highlight the rationale for 
the use and effectiveness of immunity‐targeted ap-
proaches, including targeted immunisations and non‐
specific immunomodulation in the prevention and 
management of recurrent upper RTIs.
TA B L E  1   Current preventative and evidence‐based immunity‐targeted approaches in the management of recurrent URTIs
Environmental Behavioural Nutritional Systemic
• Protection from noxious 
environmental factors (passive 
smoking, traffic‐related pollution)
• Improved hand washing
• Increased physical activity
• Avoiding crowded communities
• Zinc
• Vitamin D
• Immunisation
• Oral immunostimulators/Immunomodulators, 
for example bacterial lysates, herbal products, 
probiotics, other chemical compounds
URTI, upper respiratory tract infection.
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reducing antibacterial use and decreasing the number of work/
school absences.22,23 Immunomodulation with bacterial lysates 
is of particular interest because several randomised, controlled 
trials, summarised in systematic reviews or meta‐analyses, have 
demonstrated their efficacy in children with RTIs.19,24,25 A plausi-
ble mechanism of action for bacterial lysates has been proposed, 
which is not only based on an increase in non‐specific immuno-
globulin A response against pathogens at mucosal surfaces, but 
also on activation of mucosal dendritic cells by pattern recogni-
tion receptor‐dependent signalling.26 They act on both innate and 
adaptive immune responses, with recent findings supporting anti-
viral effects (eg increased interferon [IFN]‐γ, IFN‐α and IFN‐β).26-
28 Interestingly, application of bacterial lysates also produces 
systemic effects, including increased serum immunoglobulin con-
centrations29 and systemic CD4+ T‐helper cell responses to bac-
terial antigens. For a comprehensive review of the mechanism of 
action of bacterial lysates, see Kearney et al 2015 and Esposito et 
al 2018.21,30 Immunomodulation with bacterial lysates has been 
empirically well accepted and used by the medical community 
for decades for treating RTIs,19 and one of these commercially 
available compounds (OM‐85) has been incorporated into various 
clinical treatment guidelines such as those from the Pan American 
Association of Otorhinolaryngology and Head and Neck Surgery31 
and a European Position (EPOS) paper32 (albeit only for the man-
agement of specific chronic respiratory conditions in adults, as 
studies in children were not comprehensively evaluated) with the 
highest recommendation grade. More recently, OM‐85 has been 
recommended for the prevention of RTIs in children in several 
international guidelines.33,34 Systemic strategies include the ap-
plication of medications or dietary factors that may enhance sys-
temic immune responses, such as zinc preparation intake, vitamin 
D supplementation and probiotics; however, their clinical effec-
tiveness remains debatable.
In this review, we want to highlight emerging, evidence‐based 
approaches for conservative management of the most common re-
current and chronic URTIs in children, with an emphasis on the role 
of immunomodulation.
2  | METHODOLOGY
2.1 | Search strategy and evaluation method
Literature searches were initially conducted in March 2017 and 
then updated in September 2017 using: Academic Search Complete; 
CENTRAL; Health Source: Nursing/Academic Edition; MEDLINE; 
clinicaltrials.gov; and Cochrane databases. In total, 84 articles were 
retrieved and reviewed. Two independent researchers focused 
on the primary and secondary endpoints reported in systematic 
reviews, meta‐analyses and randomised, controlled trials, using 
immunity‐directed strategies as the control group or within a sub-
population of larger studies. Existing guidelines and interventional 
or observational studies on novel applications were also included in 
the literature searches.
2.2 | Ethical considerations
As no human participants were involved in the development of this 
review, no ethics committee (Institutional Review Board) approval 
was sought or obtained, and it was not necessary to obtain informed 
consent from patients.
3  | CROUP
3.1 | Introduction
Children with recurrent or severe croup are commonly referred to a 
paediatric otolaryngologist or ENT specialist for further assessment 
and exclusion of an underlying anatomical or congenital upper air-
way disorder.
3.2 | Epidemiology
Croup occurs at a rate of ~5/100 in the second year of life, with a 
peak incidence between 6 months and 3 years of age.35 Around 15% 
of annual clinic and emergency department visits for paediatric RTIs 
are due to croup.35 Recurrent croup in children is typically defined as 
more than three episodes.36
3.3 | Aetiology
Croup is primarily caused by parainfluenza viruses 1, 2 and 3, as well 
as RSVs. The viruses are generally spread by direct inhalation from a 
cough or sneeze, or by contamination of the hands following contact 
with fomites, with subsequent transference to the mucosa of the 
eyes, nose or mouth.
3.4 | Treatment of acute or recurrent episodes
The treatment of croup is dependent on the severity of the upper air-
way obstruction and the risk for rapid deterioration of the patient's 
condition. Mild‐to‐moderate croup is typically treated with anti‐in-
flammatory agents (nebulised or oral steroids), while adrenaline is 
required urgently in cases of severe croup.37 The use of systemic 
corticosteroids early in the disease process reduces hospitalisation 
rates,38 although 6‐10% of patients still require hospitalisation.39
3.5 | Prevention of recurrent episodes and the 
role of immunomodulation
Several evidence‐based treatment guidelines for croup are cur-
rently available online, including those from the UK,40 Australia,41 
Poland42 and Finland.43 However, these guidelines provide only 
general measures for lowering the risk of respiratory infec-
tions. There are currently no vaccines targeting the viruses re-
sponsible for croup, despite a number of attempts to develop 
them.44-46 Achieving satisfactory immunogenicity has proved 
challenging,47,48 although ongoing clinical trials (see clinicaltrials.
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gov: NCT00186927) are assessing new, well‐tolerated vaccines. 
Since most croup‐causing viruses also cause URTIs, there could 
be a therapeutic role for other immunomodulatory strategies, al-
though well‐defined, controlled studies are required.
4  | RECURRENT TONSILLITIS
4.1 | Epidemiology
Tonsillitis is more common among children than adults.49,50 In the 
USA, sore throat accounts for 2.1% of outpatient visits,51 with a 
prevalence of bacterial tonsillitis of 15‐30% among affected chil-
dren.52-54 Recurrent tonsillitis in children is defined as multiple 
episodes of acute tonsillitis in a year.55 The burden of recurrent ton-
sillitis is substantial and it may lead to peritonsillitis. However, the 
overall frequency and magnitude of the problem of recurrent tonsil-
litis remains unclear.
4.2 | Treatment of acute and recurrent episodes
The treatment of tonsillitis in children focuses on reducing symp-
toms, avoiding complications, decreasing the number of disease‐re-
lated school absences and improving quality of life. According to 
clinical practice guidelines, the first‐line treatment for bacterial ton-
sillitis should be a narrow‐spectrum antibiotic (eg penicillin).16,49,50 
However, some European countries, including Germany, the UK and 
the Netherlands, only recommend antibiotics in certain high‐risk pa-
tients.56 The widely accepted indications for tonsillectomy in children 
are at least seven well‐documented, clinically significant, adequately 
treated sore throat (defined as “acute pharyngitis, tonsillitis or acute 
exudative tonsillitis”) in the preceding year, or at least five such epi-
sodes in each of the preceding 2 years, or at least three such episodes 
in each of the preceding 3 years.49,50 Surgery should also be consid-
ered if the episodes are disabling and prevent normal functioning.
4.3 | Prevention of recurrent episodes and role of 
immunomodulation
Microbial‐derived preparations seem to offer an attractive alterna-
tive approach in prevention of tonsillitis. Firstly, in a retrospective, 
observational study of 131 children aged 1‐15 years with recurrent 
acute tonsillitis, 76% treated with a commercially available bacterial 
lysate (OM‐85) had a decrease in the frequency of acute tonsillitis 
episodes after 6 months (Figure 1).57 Most (67%) had a greater than 
50% decrease in the number of episodes, and none required a ton-
sillectomy in the subsequent long‐term follow‐up period. Secondly, 
in a 90‐day trial with the oral probiotic Streptococcus salivarius K12, 
all 30 children who completed the study had a significant reduction 
in streptococcal pharyngeal infection episodes (more than 90%) 
compared with the previous year, as well as a significant decrease 
in the incidence (80%) of oral viral infections58; no difference was 
observed in the control group. Similar results were observed in an 
earlier study.59 Finally, in a study of 160 children aged 5‐14 years 
with pharyngotonsillitis, ribosomal immunotherapy led to a signifi-
cant improvement in both specific immunity and non‐specific immu-
nity and may therefore be effective in the prophylaxis of recurrent 
pharyngotonsillitis.60
5  | OTITIS MEDIA
5.1 | Epidemiology
Acute OM (AOM) is a viral or bacterial infection of the middle ear 
and is the most common childhood infection for which antibiot-
ics are prescribed in the USA.12,61 Recurrent AOM is typically de-
fined as at least three episodes in a 6‐month period, or four or 
more episodes in a 12‐month period including at least one episode 
in the preceding 6 months.62 There are a number of risk factors 
for AOM recurrence, including the winter season, male gender 
and passive smoking.62 Approximately 50% of children aged less 
than 2 years treated for AOM experience a recurrence within 
6 months.62 Symptoms that last for more than 10 days may also 
predict recurrence.63
5.2 | Treatment of acute and recurrent episodes
The treatment approach in AOM depends on factors such as pa-
tient age and the severity of signs and symptoms.62 Non‐invasive 
treatment interventions include no treatment/ watchful waiting 
(but predisposing conditions such as immunodeficiency, anatomic 
F I G U R E  1   Bacterial‐derived 
immunomodulator in the prevention of 
acute tonsillitis (Reprinted from Bitar & 
Saade, Copyright © 2013, with permission 
from Elsevier).57 “Total response” 
was defined as a >50% decrease in 
acute tonsillitis episodes at the end of 
treatment (ie 6 months); “partial response” 
was defined as a ≤50% decrease in 
acute tonsillitis episodes at the end of 
treatment. The immunomodulator used 
was OM‐85
Improvement
76%
No response
24%
Total response
52%
Partial
 response
24%
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malformations, cystic fibrosis and ciliary dyskinesia need to be 
excluded); greater patient/parent education, such as highlighting 
the importance of avoiding passive smoking, as this is a significant 
factor impairing mucosal immunity; and breastfeeding for children 
aged less than 1 year.64 More invasive interventions, such as the 
insertion of tympanostomy tubes, may be required for children 
with recurrent AOM and one or more of the following: aged less 
than 2 years; underlying medical conditions that predispose the 
patient to recurrence; or comorbid conditions associated with de-
velopmental or language delays. However, there is generally a lack 
of consensus regarding the role of surgery in AOM.65 The parents 
of children with recurrent AOM are usually anxious about pursu-
ing a surgical treatment option and often seek complementary 
remedies.66
5.3 | Prevention of recurrent episodes and role of 
immunomodulation
A key recommendation from the guidelines of the American 
Academy of Pediatrics (AAP) is that “clinicians should NOT pre-
scribe prophylactic antibiotics to reduce the frequency of episodes 
of AOM in children with recurrent AOM.”62 Pneumococcal and in-
fluenza vaccines, given according to the schedule recommended in 
the AAP guidelines, are recommended.62 Indeed, a recent analysis 
found that the epidemiology of AOM has changed substantially 
over the past 30 years, highlighted by a decrease in the number of 
AOM episodes and the number of otitis‐prone children. The au-
thors concluded that this epidemiological shift is associated with 
the introduction of pneumococcal conjugate vaccines (PCVs) and 
also due to the development of more stringent diagnostic crite-
ria.67 Stopping smoking and banning smoking in public places sig-
nificantly decreased the rate of children's emergency department 
visits for middle ear infections and URTIs by 6‐9%, according to a 
study from Massachusetts, USA.68 Probiotics have been shown to 
be ineffective in patients with AOM.69 There may be a role for the 
use of vitamin D, since levels have been shown to be significantly 
lower in children with AOM compared with controls.70,71 There is 
also evidence that the incidence of AOM in children can be reduced 
using immunity‐targeted microbial preparations. For example, the 
frequency of AOM was assessed as a secondary endpoint in two 
clinical studies of the bacterial lysate OM‐85 involving children 
with recurrent acute RTIs. Bacterial lysate treatment reduced the 
total number of OM episodes by 68% at 6 months (n = 25 vs 8, re-
spectively)72 and by 79% at 12 months (n = 14 vs 3, respectively)73 
compared with placebo. Of note, a randomised controlled Italian 
study of OM‐85 for the prevention of URTIs (with AOM as a study 
outcome) in children with risk factors for URTIs and a history of 
recurrence is planned (EudraCT: 2016‐002705‐19). Ribosomal 
bacterial immunotherapy has also demonstrated efficacy in chil-
dren with AOM. In a study of 84 patients aged 4‐14 years, ribo-
somal immunotherapy led to a significantly improved outcome 
versus placebo on the incidence of fever, as well as the frequency 
and duration of infectious episodes.74 Ribosomal immunotherapy 
led to significant improvements in clinical score, immunological 
parameters, parents’ assessment of the patient's symptoms and 
hearing tests, compared with placebo, in a study of 72 patients 
aged 6‐14 years.75 In addition, a meta‐analysis of 19 randomised, 
double‐blind studies, including 1215 children, demonstrated a sig-
nificantly lower need for surgical procedures with ribosomal im-
munotherapy (1% vs 7% with placebo) in patients with recurrent 
AOM.76
6  | RECURRENT ACUTE AND CHRONIC 
RHINOSINUSITIS
6.1 | Epidemiology
The EPOS group defined acute rhinosinusitis (ARS) as “the sud-
den onset of two or more symptoms that last for <12 weeks.”32 
However, in older classifications the term “subacute sinusitis” was 
proposed, which represents a temporal progression of symptoms for 
4‐12 weeks (contemporarily defined as “post‐viral ARS”). Although 
chronic rhinosinusitis (CRS) is defined as persistence of sinus inflam-
mation for at least 12 weeks, the EPOS group did not feel a separate 
term to describe patients with prolonged ARS was necessary, and 
that “exacerbation of CRS” was more appropriate. In Europe, 0.5‐5% 
of children with URTIs progress to post‐viral ARS77,78 and many ex-
perience recurrences (point prevalence of 0.035%).79 Estimates of 
CRS prevalence vary significantly worldwide, partly related to dif-
ferences in the diagnostic criteria used (eg symptom‐based diagnosis 
vs inclusion of objective rhinoscopy or imaging findings). In the USA, 
the prevalence of CRS ranges from 2% to 16%, while in various EU 
countries, it is 7‐27% (average 11%).77 Estimates from South America 
and the Caribbean are in a similar range.80,81
Differentiation between recurrent ARS and CRS is difficult, but 
relies on the complete resolution of symptoms between episodes.82 
Some patients have recurrent episodes of ARS and may represent a 
distinct clinical phenotype83; these patients should be assessed for 
underlying risk factors such as allergy, immunodeficiency, cystic fi-
brosis and anatomical abnormalities,84 with consideration of imaging 
or endoscopic evaluation. As the nasal/paranasal mucosa is the first 
interface with inhaled toxins and pollutants, environmental factors 
are thought to be an important cause of transition from ARS to CRS, 
as well as the trigger for symptom exacerbation in CRS.85 For exam-
ple, there is a significant association between passive smoking and 
sinusitis.86
6.2 | Treatment of acute and recurrent episodes
Careful analysis of the underlying defect should be performed, for 
example anatomical abnormalities and immunodeficiency.87,88 The 
prophylactic treatment of recurrent episodes is almost the same as 
prevention of exacerbation of CRS, that is avoidance of smoking and 
air pollution, and handwashing to prevent infections. However, in 
our opinion, the treatment modalities for CRS in children proposed 
by the Pan American Association in 2011, the EPOS group in 2012 
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and an International Consensus Statement in 2016, need some re-
finement, since some important studies have only been published 
recently while others were overlooked. Firstly, according to a recent 
Cochrane meta‐analysis evaluating intranasal steroids for CRS in 
children, there was no effect on disease severity, although symp-
tomatic improvement (nasal blockage, rhinorrhoea, loss of sense 
of smell and facial pain) was observed.89 Based on these observa-
tions, we recommend intranasal steroids as a category Ia/A option 
for children with recurrent ARS and/or CRS.89 Secondly, in a ran-
domised, double‐blind study in 51 children, bacterial lysate OM‐85 
(recommended as a Ia/A option by EPOS for adults with CRS only, 
as studies in children were not comprehensively evaluated) not only 
improved CRS symptoms (nasal discharge and obstruction) and re-
duced the frequency of CRS exacerbations, but they also decreased 
the number of days with antibiotic use/month, providing long‐
term prophylaxis.90 Moreover, this study found that the duration 
of acute episodes was shorter with bacterial lysates than placebo, 
suggesting an additional value as a co‐medication for the treat-
ment of CRS.90 These observations were supported by two other 
randomised, double‐blind studies in children (aged 1‐9 years) with 
recurrent ARS,91,92 highlighting the clinical value of non‐specific, 
immunomodulatory approaches. Table 2 summarises the evidence 
and recommendations for the management of children with recur-
rent ARS/exacerbations of CRS as proposed by EPOS, including our 
own modifications.32 A recent international consensus statement 
also provided evidence‐based recommendations for the treatment 
of rhinosinusitis.82
6.3 | Prevention of recurrent episodes and role of 
immunomodulation
Immunisation leads to an increase in the host's resistance capabilities and 
a decrease in the incidence of acute respiratory disease.93 Vaccination 
against pneumococci with the 7‐valent pneumococcal vaccine (PCV7) re-
sulted in a significant shift in the causative pathogens of acute maxillary 
sinusitis in children; the frequency of Streptococcus pneumoniae decreased 
by 18%, but the proportion of Haemophilus influenzae increased by 8%.94 
Although there is no strong evidence of a change in the incidence of acute 
bacterial rhinosinusitis after widespread use of PCV, the H influenzae type 
b vaccine has had a positive effect.95 Another group of immune‐active 
agents, bacterial‐derived immunomodulators, has been shown to reduce 
the number of seasonal URTIs19 and decrease the frequency and inten-
sity of ARS episodes or CRS exacerbations.96 Based on evidence in adults 
with CRS without nasal polys,97 the EPOS paper and the Pan American 
Association of Otorhinolaryngology and Head and Neck Surgery guide-
lines recommend a bacterial lysate (OM‐85), although only in adults.31,32 
Nevertheless, there is substantial evidence supporting the value of bacte-
rial lysates to reduce the risk for acute RTIs in children, as evidenced by a 
Cochrane review,19 a recent large meta‐analysis of almost 5000 paediat-
ric patients25 and clinical studies highlighting the prevention of exacerba-
tions of CRS or recurrent ARS.90-92 Supported by these findings, several 
consensus papers and guidelines have noted that OM‐85 could play a role 
in the prevention of recurrent rhinosinusitis in children.33,34,98
Seasonal URTIs are the most common cause of recurrent ARS/ex-
acerbation of CRS. In a Cochrane review evaluating zinc and the com-
mon cold, which included 18 randomised controlled trials and 1781 
children and adults, it was concluded that zinc could shorten episode 
duration in children and also be used as a preventative measure99; fur-
ther research should focus on the effect of zinc in patients at a greater 
risk of developing complications after a common cold. A recent meta‐
analysis of 25 randomised controlled trials (including 11 321 children 
and adults) found that vitamin D supplementation significantly reduced 
the risk of acute RTIs, with the available evidence assessed as being 
high quality.100 Although a large number of randomised controlled trials 
have been performed assessing Echinacea and the common cold,101 the 
weakness of trial methods and differences in interventions make it dif-
ficult to draw conclusions about its effectiveness in children. Similarly, 
despite a large number of studies and wide variety of available data, ac-
cording to a systematic review, evidence supporting the use of vitamin 
C supplementation and the common cold is limited.102
7  | DISCUSSION
7.1 | Summary of main findings
Although antimicrobials retain an important role in medicine, their 
use is becoming less acceptable in modern society, particularly for 
certain conditions or when administered as a preventative measure. 
TA B L E  2   Treatment options and recommendations for children 
with recurrent ARS/CRS exacerbations (adapted from EPOS,32 with 
our own modifications90-92)
Therapy Level
Grade of 
recommendation
Nasal saline irrigation Ia A
Topical steroids Ia A
Bacterial lysates (OM‐85) Ib A
PPI/GERD therapy Low level evidence or no data
Topical antimycotics Low level evidence or no data
Oral steroids Low level evidence or no data
Probiotics Low level evidence or no data
Short‐term antibiotics 
(<4 wk)
Low level evidence or no data
Intravenous antibiotics Low level evidence or no data
Oral long‐term antibiotics Low level evidence or no data
Decongestants Low level evidence or no data
Mucolytics Low level evidence or no data
Oral/topical decongestants Low level evidence or no data
Allergen avoidance Low level evidence or no data
Allergen immunotherapy Low level evidence or no data
Systemic antimycotics Low level evidence or no data
Roman numerals indicate evidence levels; capital letters indicate 
recommendation grades. ARS, acute rhinosinusitis; CRS, chronic 
rhinosinusitis; EPOS, European Position; GERD, gastroesophageal reflux 
disease; PPI, proton‐pump inhibitor.
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The rapid emergence of resistant bacteria is jeopardising the effi-
cacy of antibiotics; indeed, decreasing the use of antibiotics is con-
sidered a top priority for healthcare authorities around the world to 
avoid the consequent effects of overuse such as an increase in an-
tibiotic resistance and mucosa microbiome impairment.103 As such, 
new treatments and preventative modalities for respiratory infec-
tions are expected and welcomed. Modulation of the human immune 
systems is becoming increasingly relevant, not only in general infec-
tious diseases, allergy or gastroenterology, but also in disciplines 
such as oncology and ENT‐related disorders. In this review, we have 
discussed the clinical evidence that supports the use of selected im-
munomodulatory strategies in children with specific ENT conditions.
7.2 | Implications for clinical practice
However, there remain some barriers to the widespread use of these 
therapies. For example, the availability of data on specific ENT in-
fections remain sparse, although evidence around the prevention of 
general RTIs is more robust. Ideally, new studies will be performed in 
specific ENT infections in children, in order to increase the evidence 
base and support treatment recommendations. In addition, accord-
ing to the available meta‐analysis, many of the commercially avail-
able products demonstrate a moderate effect.
7.3 | Future directions
As such, it is important that we generate high‐quality research data 
on the use of immunomodulatory strategies in patients with specific 
URTIs and other upper respiratory tract diseases.
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